您好,欢迎您

ASCO GI 2024来袭|学术跨年,消化肿瘤LBA+Oral+Rapid题目一览

2023年12月12日
编译:肿瘤资讯
来源:肿瘤资讯

时至岁末,新年伊始。由美国临床肿瘤学会(ASCO)、美国胃肠病学协会(AGA)、美国放射肿瘤学会(ASTRO)和美国肿瘤外科学会(SSO)共同主办的第21届美国临床肿瘤学会胃肠道肿瘤研讨会(ASCO GI 2024)将于当地时间2024年1月18日至20日以线上结合线下的形式举行,线下地点为美国旧金山Moscone West会展中心。日前,ASCO官网已公布摘要题目信息,【肿瘤资讯】特将详情整理如下,以飨读者(以下按照汇报时间先后排序)。

胃食管癌(Esophageal and Gastric Cancer)

Rapid Oral Abstract Session A: 胃食管癌

摘要号:LBA248

英文题目:A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/5 fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers (DOC-GC study)

中文题目:双臂、随机、开放标签、前瞻性设计、优效性III期DOC-GC临床试验:一项对比多西他赛-奥沙利铂-卡培他滨/5-氟尿嘧啶(DOC/F)序贯多西他赛vs.CAPOX/mFOLFOX-7治疗晚期胃癌的疗效

讲者:印度Tata纪念医院 (HBNI) Anant Ramaswamy

摘要号:249

英文题目:A randomized controlled phase III trial comparing thoracoscopic esophagectomy and open esophagectomy for thoracic esophageal cancer: JCOG1409 (MONET trial)

中文题目:JCOG1409 (MONET trial)随机对照III期试验:对比胸腔镜食管切除术vs.开放试管切除术治疗胸段食管癌的疗效

讲者:日本浜松医科大学 Hiroya Takeuchi

摘要号:250

英文题目:First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study

中文题目:KEYNOTE-590 3期试验的5年结局:一线帕博利珠单抗(pembro)联合化疗(chemo)治疗晚期食管癌

讲者:美国威尔康奈尔医学院Manish A. Shah 

摘要号:251

英文题目:A quality-adjusted time without symptoms and toxicity (Q-TWiST) analysis comparing nivolumab plus ipilimumab (N+I) or nivolumab plus chemotherapy (N+CT) versus CT in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648

中文题目:CheckMate 648:晚期食管鳞状细胞癌(ESCC)患者(pts)中比较纳武利尤单抗+伊匹木单抗vs.纳武利尤单抗+化疗(N+CT)vs.CT的质量校正无症状及毒性时间(Q-TWiST)分析

讲者:英国皇家马斯登基金会信托Ian Chau

摘要号:252

英文题目:Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648

中文题目:CheckMate 648首次全面标志物分析:纳武利尤单抗(NIVO)+化疗(chemo)或+依匹木单抗(IPI)vs.化疗作为晚期食管鳞状细胞癌(ESCC)

讲者:日本国立癌症中心医院Ken Kato

Oral Abstract Session A:胃食管癌

摘要号:LBA244

英文题目:Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial

中文题目:多中心、随机Ⅲ期试验(ESCORT-NEO):化疗联合卡瑞利珠单抗vs.化疗作为可切除食管鳞状细胞癌的新辅助治疗

讲者:中国北京 中国医学科学院肿瘤医院 李印教授

摘要号:245

英文题目:SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC)

中文题目:SKYSCRAPER-08 Ⅲ期随机、双盲、安慰剂对照试验:tiragolumab (tira) +阿替利珠单抗 (atezo) +化疗 (CT)一线治疗食管鳞状细胞癌(ESCC)

讲者:中国台湾  台湾大学医学院附属医院 许志宏(Chih-Hung Hsu)教授

摘要号:LBA246

英文题目:Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study

中文题目:基于地区的3期随机双盲MATTERHORN试验亚组分析结果:5-氟尿嘧啶-亚叶酸钙+奥沙利铂+多西他赛(FLOT)联合或不联合度伐利尤单抗(D)治疗可切除胃/胃食管交界处癌(GC/GEJC)的病理完全缓解率(pCR)

讲者:美国纪念斯隆凯特琳癌症中心 Yelena Y. Janjigian

摘要号:247

英文题目:Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: Interim analysis of the phase 3 KEYNOTE-585 study

中文题目:KEYNOTE-585 3期研究的中期分析:帕博利珠单抗联合FLOT vs.FLOT作为新辅助及辅助治疗在局部进展期胃/胃食管交界处癌

讲者:德国法兰克福大学癌症中心Salah-Eddin Al-Batran

胰腺癌、小肠癌及肝胆肿瘤(Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract)

Oral Abstract Session B:胰腺癌、小肠癌及肝胆肿瘤

摘要号:LBA588

英文题目:[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study

中文题目:[177 Lu]Lu-DOTA-TATE用于新诊断的2级和3级晚期高分化胃肠胰腺神经内分泌肿瘤患者:3期随机NETTER-2研究的初步分析

讲者:加拿大多伦多大学Sunnybrook Odette癌症中心Simron Singh

摘要号:604

英文题目:Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors

中文题目:KRAS G12C抑制剂glecirasib (JAB-21822) 在胰腺癌及其他实体瘤中的初步活性及安全性结果

讲者:中国北京 北京大学肿瘤医院 李健教授

摘要号:LBA432

英文题目:EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization

中文题目:EMERALD-1 III期、随机、安慰剂对照研究:符合栓塞适应症的不可切除肝细胞癌患者接受经动脉化疗栓塞联合度伐利尤单抗(联合或不联合贝伐珠单抗)

讲者:意大利比萨大学医学院Riccardo Lencioni

摘要号:722

英文题目:Adjuvant radiotherapy after curative resection of hepatocellular carcinoma with narrow margin (≤1 cm): A phase 2, multicenter, randomized controlled trial

中文题目:Ⅱ期多中心随机对照试验:窄切缘(≤1cm)肝细胞癌根治性切除术后接受辅助放疗 

讲者:中国广东 中山大学附属第一医院 匡铭教授

结直肠癌(Colorectal Cancer)

Rapid Oral Abstract Session C:结肠、直肠及肛门癌

摘要号:589

英文题目:NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas (GI-NECs)

中文题目:NABNEC:白蛋白结合型紫杉醇联合卡铂作为胃肠道神经内分泌癌(GI-NEC)一线治疗的随机II期研究

讲者:澳大利亚Wollongong医院Lorraine A. Chantrill

摘要号:605

英文题目:Alternating application of gemcitabine/nab-paclitaxel (Gem/nab-Pac) and Gem monotherapy or continuous application of Gem/nab-Pac after induction treatment for first-line treatment of metastatic pancreatic cancer (mPC): First results from the randomized phase 2 ALPACA study from the German AIO study group (AIO-PAK-0114)

中文题目:吉西他滨/白蛋白结合型紫杉醇(Gem/nab-Pac)和Gem单药治疗交替使用或诱导治疗后Gem/nab-Pac持续应用作为转移性胰腺癌(mPC)的一线治疗:来自德国AIO研究组(AIO-PAK-0114)的随机化II期ALPACA研究的初步结果

讲者:德国慕尼黑大学、德国癌症协会(DKTK) Klara Dorman

摘要号:433

英文题目:Hepatic arterial infusion pump chemotherapy in patients with advanced intrahepatic cholangiocarcinoma confined to the liver: A multicenter phase II trial

中文题目:肝动脉灌注化疗在晚期肝内胆管细胞癌的肝脏局部治疗:一项多中心II期临床试验

讲者:荷兰伊拉斯谟MC癌症研究所Bas Groot Koerkamp

摘要号:434

英文题目:Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial

中文题目:FGFR1-3抑制剂tinengotinib单药治疗晚期转移性胆管癌的疗效及安全性:II期临床试验

讲者:美国MD安德森癌症研究中心Milind M. Javle

摘要号:435

英文题目:Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: Results from a randomized proof-of-concept phase II trial (IMbrave151)

中文题目:概念验证性随机Ⅱ期试验(IMbrave151):阿替利珠单抗+化疗联合或不联合贝伐珠单抗在晚期胆道系统肿瘤

讲者:美国南加州大学Norris综合癌症中心Anthony B. El-Khoueiry

Rapid Oral Abstract Session C:结肠、直肠及肛门癌

摘要号:9

英文题目:Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study

中文题目:BESPOKE CRC试验中期分析:循环肿瘤DNA(ctDNA)指导II/III期结直肠癌(CRC)的辅助化疗(ACT)

讲者:美国威尔康奈尔医学院Pashtoon Murtaza Kasi

摘要号:10

英文题目:Health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) treated with sotorasib and panitumumab (pmab) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in CodeBreaK 300

中文题目:sotorasib+panitumumab (pmab)vs.曲氟尿苷替匹嘧啶(T/T)治疗转移性结直肠癌(mCRC)患者健康相关生活质量(HRQoL)

讲者:德国柏林夏里特医学院Dominik Paul Modest

摘要号:11

英文题目:Peritoneal lavage cytology in patients with curative resection for stage II and III colorectal cancer: A multi-institutional prospective study

中文题目:II期和III期结直肠癌根治性切除患者的腹腔灌洗液细胞学:一项多机构前瞻性研究

讲者:日本帝京大学附属医院Hirotoshi Kobayashi

摘要号:12

英文题目:Circulating tumor DNA analysis informing adjuvant chemotherapy in locally advanced rectal cancer: The randomized AGITG DYNAMIC-Rectal study

中文题目:随机AGITG DYNAMIC-Rectal 研究:循环肿瘤DNA分析指导局部进展期直肠癌的辅助治疗

讲者:澳大利亚Peter MacCallum癌症中心Jeanne Tie

摘要号:13

英文题目:Refining first-line treatment decision in RAS wildtype (RAS‑WT) metastatic colorectal cancer (mCRC) by combining clinical biomarkers: Results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)

中文题目:结合临床生物标志物完善RAS野生型(RAS-WT)转移性结直肠癌(mCRC)的一线治疗决策:随机III期试验FIRE-3(AIO KRK 0306)的结果

讲者:德国慕尼黑大学和德国癌症联盟(DKTK)Julian Walter Holch

Oral Abstract Session C: 结肠、直肠及肛门癌

摘要号:5

英文题目:Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study

中文题目:NRG-GI005 (COBRA) II/III 期研究:循环肿瘤DNA作为II期结肠癌辅助化疗的预测性标志物

讲者:美国MD安德森癌症中心Van K. Morris

摘要号:6

英文题目:Circulating tumor DNA (ctDNA) dynamics in patients with colorectal cancer (CRC) with molecular residual disease: Updated analysis from GALAXY study in the CIRCULATE-JAPAN

英文题目:来自GALAXY试验的CIRCULATE-JAPAN更新分析结果:循环肿瘤DNA(ctDNA)动态变化在结直肠癌(CRC)的分子残留病灶分析

讲者:日本大阪医科大学Hiroki Yukami

摘要号:7

英文题目:Organ-preservation in rectal cancer: What is at risk when offering watch and wait for a clinical complete response? Data from 2 international registries in rectal cancer

中文题目:直肠癌的器官保留:临床完全缓解的观察等待策略风险是什么?来自2项国际直肠癌登记研究的数据

讲者:葡萄牙尚帕利莫基金会Laura Melina Fernandez

摘要号:8

英文题目:Effect of laparoscopy-assisted vs open surgery on 3-year disease-free survival in patients with low rectal cancer: The LASRE randomized clinical trial

中文题目:LASRE随机临床试验:腹腔镜辅助vs.开放手术对低位直肠癌患者3年无病生存率的影响

讲者:中国福建 福建医科大学附属协和医院 池畔教授


参考文献

https://meetings.asco.org/meetings/2024-gastrointestinal-cancers-symposium/314/program-guide/scheduled-sessions

责任编辑:肿瘤资讯-Bree
排版编辑:肿瘤资讯-Astrid


版权声明
版权归肿瘤资讯所有。欢迎个人转发分享,其他任何媒体、网站如需转载或引用本网版权所有内容,须获得授权,且在醒目位置处注明“转自:良医汇-肿瘤医生APP”。